These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17897566)

  • 1. When, how, and why should sinus rhythm be restored in patients with persistent atrial fibrillation?
    Stephenson K; Tschabrunn CM; Vasu S; Rashba EJ
    Curr Treat Options Cardiovasc Med; 2007 Oct; 9(5):372-8. PubMed ID: 17897566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFFIRM and RACE trials: implications for the management of atrial fibrillation.
    Blackshear JL; Safford RE; ;
    Card Electrophysiol Rev; 2003 Dec; 7(4):366-9. PubMed ID: 15071255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate versus rhythm control in atrial fibrillation.
    Wijffels MC; Crijns HJ
    Cardiol Clin; 2004 Feb; 22(1):63-9. PubMed ID: 14994848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of atrial fibrillation.
    Hersi A; Wyse DG
    Curr Probl Cardiol; 2005 Apr; 30(4):175-233. PubMed ID: 15778690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trial.
    Guglin M; Chen R; Curtis AB
    Heart Rhythm; 2010 May; 7(5):596-601. PubMed ID: 20159046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of symptomatic atrial fibrillation.
    Haghi D; Schumacher B
    Am J Cardiovasc Drugs; 2001; 1(2):127-39. PubMed ID: 14728042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.
    Chung MK; Shemanski L; Sherman DG; Greene HL; Hogan DB; Kellen JC; Kim SG; Martin LW; Rosenberg Y; Wyse DG;
    J Am Coll Cardiol; 2005 Nov; 46(10):1891-9. PubMed ID: 16286177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
    Boriani G; Diemberger I; Biffi M; Martignani C; Branzi A
    Drugs; 2004; 64(24):2741-62. PubMed ID: 15563247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
    Crijns HJ
    Drugs; 2005; 65(12):1651-67. PubMed ID: 16060699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
    Li D; Sun H; Levesque P
    Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
    Sherman DG; Kim SG; Boop BS; Corley SD; Dimarco JP; Hart RG; Haywood LJ; Hoyte K; Kaufman ES; Kim MH; Nasco E; Waldo AL;
    Arch Intern Med; 2005 May; 165(10):1185-91. PubMed ID: 15911734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation.
    Ling LH; Taylor AJ; Ellims AH; Iles LM; McLellan AJ; Lee G; Kumar S; Lee G; Teh A; Medi C; Kaye DM; Kalman JM; Kistler PM
    Heart Rhythm; 2013 Sep; 10(9):1334-9. PubMed ID: 23811081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.
    Morillo CA; Verma A; Connolly SJ; Kuck KH; Nair GM; Champagne J; Sterns LD; Beresh H; Healey JS; Natale A;
    JAMA; 2014 Feb; 311(7):692-700. PubMed ID: 24549549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.
    Nattel S; Khairy P; Roy D; Thibault B; Guerra P; Talajic M; Dubuc M
    Drugs; 2002; 62(16):2377-97. PubMed ID: 12396229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation.
    Hagens VE; Van Gelder IC; Crijns HJ;
    Card Electrophysiol Rev; 2003 Jun; 7(2):118-21. PubMed ID: 14618033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cardioversion efficacy of nifekalan in patients with sustained atrial fibrillation after radiofrequency ablation].
    Li F; Xia Z; Yu JH; Chen Q; Hu JZ; Zhu B; Xia ZR; Huang QH; Li JX; Hong K; Wu YQ; Cheng XS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Dec; 47(12):963-968. PubMed ID: 31877591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.